Dual Antiplatelet Therapy in Coronary Artery Disease: New Guidelines and Beyond
- CME / AMA PRA Category 1 Credit™
Subsequent to the recording of this program, the results of two important clinical trials, TWILIGHT and ISAR-REACT-5, were published. Click here for a PDF of the content with slides added that outline the results of these trials.
It is estimated that 720,000 Americans will have a new coronary event and 335,000 will have a recurrent event this year. Guidelines recommend that these patients receive dual antiplatelet therapy (DAPT) with low-dose ASA and a platelet P2Y12 receptor antagonist (clopidogrel, prasugrel, or ticagrelor). While there is agreement that low-dose ASA therapy should be continued indefinitely, research continues to lead to modifications of the recommendations for P2Y12 receptor antagonists. To address this, in 2016 the ACC and AHA jointly published a focused guideline update on the use of DAPT in CAD. However, many clinicians are not yet following these recommendations, either because they are not familiar with them or because they are skeptical about the applicability of randomized clinical trials to their practices.
Dual Antiplatelet Therapy in Coronary Artery Disease: New Guidelines and Beyond will review the 2016 ACC/AHA guideline update for the use of DAPT in CAD and outline the real-world evidence for these recommendations. In addition, the activity will discuss the findings from studies completed after the guidelines were published that clinicians may find useful when developing individualized DAPT management strategies for their patients with CAD.
Welcome and Introductions
Guidelines on the Use of DAPT in CAD
What’s New Since the Guidelines?
This activity is intended for cardiologists who manage patients at risk for or with CAD.
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this activity, participants should be able to:
- Apply the 2016 ACC/AHA guideline focused update on DAPT recommendations when developing individualized management plans for patients with CAD
- Consider the results of recent clinical trials investigating the optimal management of DAPT when creating management plans for patients with CAD
- Identify validated tools that can be used to individualize DAPT therapy
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of North Texas Health Science Center and Rockpointe. The University of North Texas Health Science Center is accredited by the ACCME to provide continuing medical education for physicians.
The University of North Texas Health Science Center designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Associate Professor of Medicine
Director of Health Services Research
Dr. Wang is a health services researcher with expertise in implementation science and pragmatic clinical trials. She has led several cardiovascular clinical trials and registries at the Duke Clinical Research Institute (DCRI) that have focused on comparative effectiveness and safety, health disparities, care quality assessment and quality improvement. To date, she has published more than 250 manuscripts on these topics. She was the Principal Investigator of the ARTEMIS randomized clinical trial studying the impact of copayment reduction on antiplatelet medication adherence and outcomes after myocardial infarction. She has lectured widely on the use of “big data” to identify treatment gaps for intervention and has led projects using data solutions to design and implement quality-improvement initiatives. In addition, she is interested in evolving the platform for research to improve site and patient recruitment, innovate longitudinal patient follow-up, enrich the collection of patient-reported outcomes, pragmatically adjudicate clinical events of interest, and add important health economic insights.
Dr. Wang chaired the American Heart Association’s Quality of Care and Outcomes Research Council from 2017-2019, and serves on many task forces, committees, and writing groups for the American Heart Association, American College of Cardiology, and American College of Physicians. She is an Associate Editor of the JAMA Internal Medicine journal. She is the Director of Health Services and Outcomes Research at the DCRI and remains a practicing noninvasive cardiologist with both inpatient and outpatient responsibilities.
Director, Cardiac Intensive Care Unit
Johns Hopkins Bayview Medical Center
Associate Professor of Medicine
Division of Cardiology
Johns Hopkins University
She was the recipient of a National Institutes of Health (NIH) Career Mentored Award (K23) examining platelet functional genomics and an NIH RO1 Award addressing platelet serotonin signaling in depression and heart disease. Dr. Williams has several publications covering platelet functional changes in settings of interventional cardiology, acute coronary syndrome, and heart disease and depression. She has participated in several National Heart, Lung, and Blood Institute (NHLBI) advisory committees, review groups, and study sections.
Dr. Williams received her undergraduate degree in biochemistry from McGill University. She earned a medical degree from the Columbia University College of Physicians and Surgeons and completed a residency at Johns Hopkins Hospital. Dr. Williams was a cardiology fellow at Mount Sinai Hospital and Johns Hopkins Hospital and is currently Director of the Cardiac Intensive Care Unit at Johns Hopkins Bayview Medical Center.
Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA: Research: AstraZeneca, Bristol-Myers Squibb, Cryolife, Portola, Regeneron; Consultant/Advisory Board: AstraZeneca, Sanofi
Marlene S. Williams, MD, FACC: Advisory Board: Haemonetics
NON-FACULTY CONTENT CONTRIBUTOR DISCLOSURES
Terry Ann Glauser, MD, MPH; Blair St. Amand; INCEDO: Nothing to disclose
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
Jointly provided by University of North Texas Health Science Center and Rockpointe
This program is conducted in collaboration with Mended Hearts.
This program is supported by an unrestricted educational grant from AstraZeneca.
Incorporating New Guidelines to Lower LDL-C and Reduce ASCVD Risk
Credits 1.00 (60 min)
Updates on Blood Cholesterol: Applying new Guidelines to Clinical Practice
Credits >1.00 (>60 min)
Improving Outcomes for Patients with Severe Hypercholesterolemia
Credits 1.00 (60 min)